Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury

Abstract

IntroductionAcute lung injury (ALI) is a devastating condition that places a heavy burden on public health resources. Although the need for effective ALI prevention strategies is increasingly recognised, no effective preventative strategies exist. The Lung Injury Prevention Study with Aspirin (LIPS-A) aims to test whether aspirin (ASA) could prevent and/or mitigate the development of ALI.Methods and analysisLIPS-A is a multicentre, double-blind, randomised clinical trial testing the hypothesis that the early administration of ASA will result in a reduced incidence of ALI in adult patients at high risk. This investigation will enrol 400 study participants from 14 hospitals across the USA. Conditional logistic regression will be used to test the primary hypothesis that early ASA administration will decrease the incidence of ALI.Ethics and disseminationSafety oversight will be under the direction of an independent Data and Safety Monitoring Board (DSMB). Approval of the protocol was obtained from the DSMB prior to enrolling the first study participant. Approval of both the protocol and informed consent documents were also obtained from the institutional review board of each participating institution prior to enrolling study participants at the respective site. In addition to providing important clinical and mechanistic information, this investigation will inform the scientific merit and feasibility of a phase III trial on ASA as an ALI prevention agent. The findings of this investigation, as well as associated ancillary studies, will be disseminated in the form of oral and abstract presentations at major national and international medical specialty meetings. The primary objective and other significant findings will also be presented in manuscript form. All final, published manuscripts resulting from this protocol will be submitted to Pub Med Central in accordance with the National Institute of Health Public Access Policy.

Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation

“…MPs are small cell-derived vesicles released from activated cells, playing an important role in intracellular communication. More specifically, MPs are generated by platelets and endothelial cells, as an effect of various triggering factors, including mechanical injury and inflammation [58] . They contain several enzymes and proteins, which serve as biological signals, promoting information exchange.…”

Favorable Neurocognitive Outcome with Low Tidal Volume Ventilation after Cardiac Arrest

“…The propensity score was developed using logistic regression to estimate the probability of receiving low (<8 ml/kg PBW) compared with high (.8 ml/kg PBW) VT. This dichotomized VT threshold was chosen to reflect current standard practice for lung-protective VT, stemming from the ARDS Network protocol that targeted VT of 4 to 8 ml/kg PBW (9) and the U.S. Critical Illness and Injury Trials Group Checklist for Lung Injury Prevention recommendation for VT of 6 to 8 ml/kg PBW in patients at risk for lung injury (32,33). The final propensity model was chosen to represent current understanding of underlying biology and ensure face validity.…”

Recent Advances in the Management of the Acute Respiratory Distress Syndrome

“…6 These and other best practices, such as fluid management and early antibiotics in the setting of sepsis can be bundled into a Checklist for Lung Injury Prevention. 6,115 Early Identification As previously described, much of the reduction in incident cases of ARDS over time has been caused by reductions of nosocomial ARDS. 6 However, approaches that identify patients with or those who are likely to develop ARDS early could provide new opportunities not only for prevention but also to limit syndrome severity when it does occur.…”